Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-guided pre-emptive valganciclovir therapy for cytomegalovirus antigenemia in immunosuppressed rheumatology inpatients
jRCTs051240080Recruiting
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valganciclovir in cytomegalovirus disease (CMV). Started Sep 2024; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCTs051240080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240080.